Gefitinib, 5-fluorouracil, leucovorin and radiotherapy
Phase 1/2TerminatedDevelopment Stage
Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC
Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC
Jul 1, 2003 → Feb 1, 2004
About Gefitinib, 5-fluorouracil, leucovorin and radiotherapy
Gefitinib, 5-fluorouracil, leucovorin and radiotherapy is a phase 1/2 stage product being developed by AstraZeneca for Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC. The current trial status is terminated. This product is registered under clinical trial identifier NCT00237900. Target conditions include Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC.
What happened to similar drugs?
6 of 16 similar drugs in Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00237900 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC